MedTrace Logo

A Phase II Study of TollB-001 Tablets in Systemic Sclerosis

NCT07745725 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-08-04

No results posted yet for this study

Summary

The goal of this Phase II study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of TollB-001 Tablets in adults aged 18 to 70 years (male or female) with systemic sclerosis (SSc).

Conditions

  • Systemic Sclerosis (SSc)

Interventions

DRUG

TollB-001 Tablet

TollB-001 Tablets

DRUG

Placebo

Placebo Tablets

Sponsors & Collaborators

  • Toll Biotech Co. Ltd. (Beijing)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-10-31
Completion
2028-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07745725 on ClinicalTrials.gov